Based on the Indaptus Therapeutics Inc stock forecast from 1 analysts, the average analyst target price for Indaptus Therapeutics Inc is USD 5.00 over the next 12 months. Indaptus Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Indaptus Therapeutics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Indaptus Therapeutics Inc’s stock price was USD 0.85. Indaptus Therapeutics Inc’s stock price has changed by -4.49% over the past week, -18.27% over the past month and -51.57% over the last year.
No recent analyst target price found for Indaptus Therapeutics Inc
No recent average analyst rating found for Indaptus Therapeutics Inc
Company Overview Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. Read Less
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatoce...Read More
Frequently Asked Questions About Indaptus Therapeutics Inc (INDP) Stock
Based on ratings from 1 analysts Indaptus Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on INDP's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for INDP is USD 5.00 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on INDP's stock to indicate if its overvalued.
The last closing price of INDP's stock was USD 0.85.
The most recent market capitalization for INDP is USD 0.01B.
Based on targets from 1 analysts, the average taret price for INDP is projected at USD 5.00 over the next 12 months.
This means that INDP's stock price may go up by +488.24% over the next 12 months.
We can't find any ETFs which contains Indaptus Therapeutics Inc's stock.
As per our most recent records Indaptus Therapeutics Inc has 7 Employees.
Indaptus Therapeutics Inc's registered address is Three Columbus Circle, New York, NY, United States, 10019.
You can get more information about it from Indaptus Therapeutics Inc's website at https://indaptusrx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Indaptus Therapeutics Inc (INDP) Stock
Based on ratings from 1 analysts Indaptus Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on INDP's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for INDP is USD 5.00 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on INDP's stock to indicate if its overvalued.
The last closing price of INDP's stock was USD 0.85.
The most recent market capitalization for INDP is USD 0.01B.
Based on targets from 1 analysts, the average taret price for INDP is projected at USD 5.00 over the next 12 months.
This means that INDP's stock price may go up by +488.24% over the next 12 months.
We can't find any ETFs which contains Indaptus Therapeutics Inc's stock.
As per our most recent records Indaptus Therapeutics Inc has 7 Employees.
Indaptus Therapeutics Inc's registered address is Three Columbus Circle, New York, NY, United States, 10019.
You can get more information about it from Indaptus Therapeutics Inc's website at https://indaptusrx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for INDP !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
